

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/591,195
Filing Date September 29, 2006
First Named Inventor Liat Hayardeny
Art Unit 1649
Examiner Name Kolker, Daniel E.
Attorney Docket Number 68051-B-PCT-US/JPW

Sheet 1 of 5

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/D.K./	1	US-5,800,808	09-01-1998	Konfino, et al.	
	2	US-5,981,589	11-09-1999	Konfino, et al.	
	3	US-6,048,898	04-11-2000	Konfino, et al.	
	4	US-6,054,430	04-25-2000	Konfino, et al.	
	5	US-6,214,791	04-10-2001	Amon, et al.	
	6	US-6,342,476	01-29-2002	Konfino, et al.	
	7	US-6,362,161	03-26-2002	Konfino, et al.	
	8	US-6,514,938	02-04-2003	Gad, et al.	
	9	US-6,620,847	09-16-2003	Konfino, et al.	
	10	US-6,800,285	10-05-2004	Rodriguez	
	11	US-6,800,287	10-05-2004	Gad, et al.	
	12	US-6,939,539	09-06-2005	Konfino, et al.	
	13	US-7,022,663	04-04-2006	Gilbert, et al.	
	14	US-7,033,582	04-25-2006	Yong, et al.	
	15	US-7,074,580	07-22-2006	Gad, et al.	
	16	US-7,163,802 B2	01-16-2007	Gad, et al.	
	17	US-7,199,098	04-03-2007	Konfino, et al.	
	18	US-7,279,172	10-09-2007	Aharoni, et al.	
	19	US-2003-017029 A1	09-11-2003	Klinger	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ Number "Kind Code" (if known)				
/D.K./	29	WO 98/30227	07-16-1998	Yeda Research and Development CO., LTD.		
	30	WO 00/05250	02-03-2000	Yeda Research and Development CO., LTD.		
	31	WO 00/18794	04-06-2000	Yeda Research and Development CO., LTD.		
	32	WO 00/27417	05-18-2000	Yeda Research and Development CO., LTD.		
	33	WO 01/60392	08-23-2001	Yeda Research and Development CO., LTD.		
	34	WO 01/93828	12-13-2001	Teva Pharmaceuticals Industries, LTD.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Liat Hayardeny, et al.
Filed: \$371 national stage of PCT
International Application No.
PCT/US2005/007072, filed March 3,
2005
ExhibitA

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/591,195
Filing Date	September 29, 2006
First Named Inventor	Liat Hayardeny
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	68051-B-PCT-US/JPW

Sheet 2 of 5

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.K./	20	US- 2005-0170004	08-04-2005	Rosenberger	
	21	US- 2006-0122113	06-08-2006	Pinchasi, et al.	
	22	US- 2006-0172942 A1	08-03-2006	Dolitzky	
	23	US- 2006-0052586	03-09-2006	Dolitzky	
	24	US- 2007-0021341 A1	01-25-2007	Sela, et al.	
	25	US- 2007-0021324 A1	01-25-2007	Dolitzky, et al.	
	26	US- 2007-0048794 A1	03-01-2007	Gad, et al.	
	27	US- 2007-0054857	03-08-2007	Pinchasi, et al.	
	28	US- 11/590,338	10-30-2006	Pinchasi, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.K./	35	WO 01/97846	12-27-2001	Teva Pharmaceuticals Industries, LTD.	
	36	WO 03/048735	06-12-2003	Teva Pharmaceuticals Industries, LTD.	
	59	WO 04/43995	05-27-2004	APOTEX PHARMACHEM INC.	
	60	WO 06/50122	05-11-2006	Sandoz AG	
	61	WO 08/06026	01-10-2008	MOMENTA PHARMACEUTICALS, INC.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, 4000 Randolph Blvd., Alexandria, VA 22313-1450. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/591,195
Filing Date	September 29, 2006
First Named Inventor	Liat Hayardeny
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	68051-B-PCT-US/JPW

Sheet	3	of	5
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.K./	37	Bornstein et al., "Treatment of MS with a Synthetic Polypeptide: Preliminary Results" Ann. Neurol., 1980, 8, 117 ABSTRACT	
/D.K./	38	Bornstein et al., "Treatment of MS with synthetic polypeptide: preliminary results" Trans. Am. Neurol. Assoc., 1980, 105, 348-350	
/D.K./	39	Bornstein et al., "MS: Trial of a synthetic polypeptide" Ann. Neurol., 1982, 11, 317-319	
/D.K./	40	Bornstein et al., "Clinical trials of Copolymer 1 in MS" Ann. N.Y. Acad. Sci. (USA), 1984, 366-372	
/D.K./	41	Bornstein et al., "Clinical Trials of a synthetic polypeptide (Copolymer 1) for the treatment of MS" Immunol. & Clin. Aspects of MS, 1984, 144-150	
/D.K./	42	Bornstein et al., "MS: Clinical Trials of a Synthetic Polypeptide, Copolymer 1" Neurol., 1985, 35 (Suppl. 1), 103 ABSTRACT	
/D.K./	43	Bornstein, "Cop 1 may be beneficial for patients with exacerbating remitting form of MS" Adv. Ther., 1987, 4, 206 ABSTRACT	
/D.K./	44	Bornstein, et al., "A Pilot trial of Cop 1 in Exacerbating remitting MS" New Eng. J. Med., 1987, 317 (7), 408-414	
/D.K./	45	Bornstein, et al., "Clinical Experience with COP-1 in MS" Neurol., 1988, 38 (Suppl. 2.), 66-69	
	46	Bornstein, et al., "Rationale for Immunomodulating Therapies of MS" Neurol., 1988, 38 (Suppl. 2.), 80-8111	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/591,195
Filing Date	September 29, 2006
First Named Inventor	Liat Hayardeny
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	68051-B-PCT-US/JPW

Sheet	4	of	5
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.K./	47	Bornstein et al., "Pilot Trial of COP-1 in Chronic Progressive MS: Preliminary report" Intl. MS Conf.1988, in Elsevier Sci. Publi. 1989, 225-232	
/D.K./	48	Bornstein et al., "Clinical Trials of Cop 1 in MS" Handbook of MS, 1990, 469-480	
/D.K./	49	Bornstein et al., "A Placebo-controlled, Double-Blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive MS" Neurol., 1991, 41, 533-539	
	50	Bornstein et al., "Treatment of MS with Copolymer 1" Treatment of MS, Trial Design, 1992, 173-198 US\$5,800,000	
/D.K./	51	Bornstein, "Clinical Experience: Hopeful Prospects in MS," Hosp Prac. (Off. Ed.) May 15, 1992 vol. 27 (No. 5) L135-138, 141-142, 145-158	
/D.K./	52	Kalkers et al., "The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study" in Multiple Sclerosis, 2002, vol. 8, issue 6, pages 532-533	
/D.K./	53	Sela et al., "Glatiramer acetate in the treatment of multiple sclerosis" in Expert Opin. Pharmacother., 2001, vol.2, no.7, pages 1149-1165	
/D.K./	54	Copaxone® (glatiramer acetate injection), prescribing information, http://www.copaxone.com/pdf/PrescribingInformation.pdf No date	
/D.K./	55	International Preliminary Report on Patentability issued by the International Bureau of WIPO dated December 24, 2007 in connection with International Application No. PCT/US2005/000702	
/D.K./	56	PCT International Search Report issued November 30, 2007 for International Application Publication No. PCT/US2005/000702	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.